Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1671 participants.

Also called NCT02699645

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 1,671 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02699645
Other papers using this trial's data
  • Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage The New England journal of medicine, 2026-04-23 DOI, PubMed 42019018

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Brazil, Georgia, Malaysia, Netherlands, Nigeria, Singapore, Sri Lanka, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02699645. Randomized; quadruple masking; primary purpose prevention. Start 2017-09-28 (actual); primary completion 2025-08-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial
Acronym
TRIDENT
Condition
Intracerebral Haemorrhage (ICH)
Condition
Hypertension
Intervention (Drug)
telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg
Intervention (Drug)
Placebo
Lead sponsor
The George Institute (class: other)
Collaborator
The University of New South Wales (class: other)

Record details

Record id
cardio:ct-nct02699645
Content hash
506dc0d1c58581d857867ed4e4d167f81b6518c3eb6d20de9c9625ce53ee4bef